surmount-1 tirzepatide obesity nejm 2022 weight loss percent 📊 Semaglutide 2.4mg: −13.7% (SURMOUNT-5 head-to-head), 📊 15mg: −20.2% weight loss (same trial, 2025), 📊 Retatrutide 12mg: −28.7% weight loss (TRIUMPH-4, Phase 3, Dec Tirzepatide for the Treatment of

Most research protocols use 100 to 300 mcg per shot , one to three times per day

Peptide therapy is popular for its relatively low side effects

There have been rare reports of pancreatitis (inflammation of the pancreas) in patients taking GLP-1 receptor agonists, though a definitive causal relationship remains uncertain

Daily moderate activity can reduce stress and improve sleep, but avoid intense workouts right before bed

The projected timeline for remaining pivotal trials is early to mid-2026, with data publication expected shortly thereafter

Unlike Mounjaro and Zepbound, which come in injection pens, our compounded tirzepatide is provided in vials with syringes